DermaFlow

DermaFlow has developed a non-invasive proprietary and patented technology that accurately and cost effectively measures directly peripheral (in the capillaries) blood flow and detects tell-tale changes in microcirculation. It has been estimated that ~ 90% of disease results in microcirculation changes, and therefore having a "friendly"​ and affordable way to monitor this routinely is of significant value to modern healthcare.

This technology lends itself easily and expediently to three major healthcare trends:
*stream-lined 510 K predicate regulatory track designated (for a stand-alone device)
* wireless monitoring for home and remote situations
* integration into existing monitoring and/or sensing devices

DermaFlow has completed early proof-of-concept clinical studies, and is focusing currently on acute care (sepsis in ICU patients) with its first stand alone product Perichek Multi.

In addition, Dermaflow has completed development of Perichek - a module suitable for integration into established patient monitoring suites.

Dermaflow technology has a wide range of applications in acute and chronic care, both in and out of hospital.

We welcome interested corporate, clinical, and strategic partners as well as accredited investors.